Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: utilizing host and pathogen biomarkers to enhance the TB elimination strategies DOI Creative Commons
Tonino Alonzi, Elisa Petruccioli, Alessandra Aiello

и другие.

International Journal of Infectious Diseases, Год журнала: 2025, Номер unknown, С. 107880 - 107880

Опубликована: Март 1, 2025

Tuberculosis (TB) remains the leading cause of death worldwide from a single infectious disease. An estimated quarter world's population, about 2 billion people, has an immune response to Mtb without clinical, microbiological, or radiological signs TB This condition is known as infection (TBI) and carries lifelong risk reactivation with 5-10% individuals eventually developing disease during their lifetime. IGRA skin-tests are World Health Organization (WHO)-approved tests for TBI diagnosis allow identify those needing preventive therapy. The WHO End Strategy proposes several approaches mitigate global burden TB. Achieving goal elimination requires improved early at disease, provision therapy, development new diagnostic address current limitations. review provides update on currently used offers overview experimental based either host analysis pathogen detection. Additionally, we briefly report tests, such RNA signatures, which can help identifying high progressing towards Although these show promise, further investigation randomized clinical trials required establish reliable proof-of-concept.

Язык: Английский

Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: utilizing host and pathogen biomarkers to enhance the TB elimination strategies DOI Creative Commons
Tonino Alonzi, Elisa Petruccioli, Alessandra Aiello

и другие.

International Journal of Infectious Diseases, Год журнала: 2025, Номер unknown, С. 107880 - 107880

Опубликована: Март 1, 2025

Tuberculosis (TB) remains the leading cause of death worldwide from a single infectious disease. An estimated quarter world's population, about 2 billion people, has an immune response to Mtb without clinical, microbiological, or radiological signs TB This condition is known as infection (TBI) and carries lifelong risk reactivation with 5-10% individuals eventually developing disease during their lifetime. IGRA skin-tests are World Health Organization (WHO)-approved tests for TBI diagnosis allow identify those needing preventive therapy. The WHO End Strategy proposes several approaches mitigate global burden TB. Achieving goal elimination requires improved early at disease, provision therapy, development new diagnostic address current limitations. review provides update on currently used offers overview experimental based either host analysis pathogen detection. Additionally, we briefly report tests, such RNA signatures, which can help identifying high progressing towards Although these show promise, further investigation randomized clinical trials required establish reliable proof-of-concept.

Язык: Английский

Процитировано

1